LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.Acta Derm Venereol | PMID 42272192PMC13253760 | 2026-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Neurology已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 42096672PMC13165287 | 2026-Jun-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42100960PMC13156798 | 2026-Jun-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| [Efficacy and safety of combining olorigliflozin with metformin in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy].Zhonghua Yi Xue Za ZhiPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42252239无 PMCID | 2026-Jun-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.J Crohns Colitis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 other;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图;另有 1 张未列出。 | PMID 42309525PMC13275131 | 2026-Jun-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42119587无 PMCID | 2026-Jun-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.Oncologist | PMID 42179186PMC13257860 | 2026-Jun-06 | 0.90 | The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results, but the primary and key secondary endpoints are proportion-based (spleen volume reduction, symptom score reduction) and are not time-to-event outcomes. No time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) is reported or mentioned. | 已完成 |
| Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42214397无 PMCID | 2026-Jun-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.Blood | PMID 41758929PMC13277651 | 2026-Jun-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.J Pharmacokinet Pharmacodyn已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。 | PMID 42243460PMC13236835 | 2026-Jun-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41967349无 PMCID | 2026-Jun-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42019226无 PMCID | 2026-Jun-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).J Neurol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图。 | PMID 42234197PMC13233976 | 2026-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42096239PMC13154035 | 2026-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42099212PMC13156799 | 2026-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer.J Natl Cancer InstPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40880294无 PMCID | 2026-Jun-01 | 0.95 | The report focuses on long-term benign event rates and endometrial safety in a prevention trial, not the primary or key secondary time-to-event efficacy endpoint of the oncology trial. | 无 KM 图 |
| Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.Int J Radiat Oncol Biol Phys | PMID 41285272PMC13052378 | 2026-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.Diabetes Care疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图。 | PMID 41296499PMC13191423 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.Clin Cancer Res | PMID 41504634PMC13223540 | 2026-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effects of a structured exercise program on motivational outcomes in patients with colon cancer.J Natl Cancer Inst疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:AI 判定为 other;Figure 3.:非 KM 图;Figure 4.:非 KM 图。 | PMID 41609410PMC13247338 | 2026-Jun-01 | 0.90 | The study is a randomized, phase 3 oncology trial in human colon cancer patients. However, the reported intervention is a structured exercise program (non-drug), and the primary outcomes are motivational/social cognitive beliefs (not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.). No drug-containing intervention is described. | 无 KM 图 |
| Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.Inflamm Bowel Dis已检查 6 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 1 张未列出。 | PMID 41655066PMC13233136 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41711624无 PMCID | 2026-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.Inflamm Bowel Dis已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:森林图/亚组分析图;Figure 4:研究设计图;Figure 5:AI 判定为 other;另有 2 张未列出。 | PMID 41777218PMC13233144 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial.JAMA PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41811299PMC12980359 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.Clin Cancer Res | PMID 41837753PMC13223549 | 2026-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Results of the Pediatric Guideline Adherence and Outcomes (PEGASUS) Program Versus Usual Care Pragmatic Randomized Controlled Trial in Severe Traumatic Brain Injury.Crit Care MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41891786无 PMCID | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.JAMA Psychiatry已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图。 | PMID 41920558PMC13044789 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cerebral Oximetry in Extremely Preterm Infants: 2-Year Follow-Up of the SafeBoosC-III Randomized Clinical Trial.JAMA Pediatr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure.:非 KM 图。 | PMID 42008246PMC13097032 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.JAMA Ophthalmol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:AI 判定为 other;Figure 3.:AI 判定为 other。 | PMID 42024409PMC13107309 | 2026-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.JAMA Oncol | PMID 42060297PMC13133723 | 2026-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.JAMA Netw Open | PMID 42295761PMC13270272 | 2026-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial.Asian Pac J Cancer Prev疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42345146无 PMCID | 2026-Jun-01 | 0.90 | The study is a Phase III randomized controlled trial with a primary time-to-event endpoint (PFS) for a human malignant neoplasm (high-grade glioma). However, the randomized intervention is a comparison of radiotherapy target volume margins (reduced-margin vs. standard RTOG-protocol), not a drug-containing intervention. The abstract does not describe a drug-containing arm as part of the randomized comparison; 'adjuvant chemoradiation' in the title likely refers to the overall treatment context, not the experimental variable being tested. | 无 KM 图 |
| Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial.J Am Acad Child Adolesc PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40619095无 PMCID | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Breast Cancer Patients With Brain Metastases-A Phase 3 Open Label Randomized Study.Asia Pac J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40983872无 PMCID | 2026-Jun | 0.95 | Study meets all criteria except drug intervention. It is a Phase III randomized trial in human oncology with primary time-to-event endpoints (OS, PFS), but compares two radiotherapy techniques (WBRT vs SRS) without a drug-containing arm. The required drug intervention is not present. | 无 KM 图 |
| Neonatal morbidity in early-onset fetal growth restriction with and without anticoagulant therapy.Pediatr ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41034645无 PMCID | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41073155无 PMCID | 2026-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41193271无 PMCID | 2026-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.Diabetologia入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41272211无 PMCID | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.Int J Dermatol | PMID 41272415PMC13161509 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.J Eur Acad Dermatol Venereol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:森林图/亚组分析图。 | PMID 41297955PMC13206257 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial.Allergy疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。 | PMID 41444697PMC13256269 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.Arthritis RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41466456无 PMCID | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.Ann Surg Oncol | PMID 41535566PMC13179169 | 2026-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41571045无 PMCID | 2026-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.J Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41580093无 PMCID | 2026-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.Lancet Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::非 KM 图;Figure 4::森林图/亚组分析图。 | PMID 41619753PMC13040453 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41621752无 PMCID | 2026-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41642173无 PMCID | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.J Eur Acad Dermatol Venereol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:AI 判定为 flow diagram;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 multi panel km。 | PMID 41678327PMC13206364 | 2026-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41687718无 PMCID | 2026-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |